CSL shares have underperformed the ASX 200 over the past month. What's going on?

The CSL Limited (ASX :CSL) share price has underperformed the ASX 200 over the past month. What's going on with CSL shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has done the unthinkable and actually underperformed the broader S&P/ASX 200 Index (ASX: XJO) over the past month.

To be frank, CSL shares normally beat the pants off the market. It managed to do this both in the 2016–2020 bull market and in the short-but-sharp bear market we saw in February and March of this year.

But since mid-April, CSL shares have actually fallen around 10%, whilst the ASX 200 has rallied around 7% over the same period.

What's going on?

Has CSL lost its magic?

Well, in my opinion, the recent underperformance of CSL shares has nothing to do with the company itself. CSL hasn't yet told the markets if it expects any material hit to revenue or earnings as a result of the coronavirus pandemic (apart from disruption to plasma collections). CSL isn't actively joining the race for a COVID-19 vaccine, but (as Fool contributor Nikhil Gangaram pointed out today) the company is working on antibody-based medicines that will allow patients to recover faster without the use of a ventilator.

We do know that CSL has obtained additional capital (US$750 million at 2.68%) through the bond market recently, but again, this doesn't indicate anything of significance for investors in my view.

So no, I don't think CSL has lost its magic.

Instead, I view the pullback in the CSL share price as a sign that investors might have got a little ahead of themselves in April.

CSL shares reached lows of $270.88 in March, but by 9 April, CSL was back to $329 a share, just below the all-time high of $342.75 that we saw in February.

Given what's going on in the global economy, it's possible investors decided this run-up was a little optimistic, and that's why we are seeing a more subdued CSL share price in recent weeks.

Are CSL shares a buy today?

Although I've long thought CSL is a top company, it's also a little too highly priced for me to consider a buy today. Even on today's share price of $298.27, the company is still asking a price-to-earnings (P/E) ratio of 44.28. That's a fairly high number for the ASX's largest company, and one I don't think is entirely justified by CSL's future growth prospects.

I might be waiting a while, but CSL is still not in the buy zone for me, despite its resilience and quality as a business.

Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »